Luciferase Reporter Cancer Cell Lines

CAR-T cell-based therapeutics have emerged as a promising immunotherapy for treating specific leukemias, lymphomas, and myelomas. In this exciting approach to treating refractory cancers, T cells are isolated from a patient’s blood via apheresis. The cells are then incubated with the cytokine interleukin 2 and anti-CD3 antibodies to stimulate proliferation. Ex vivo silencing of genes involved in graft rejection is conducted to aid in improving T-cell stability after infusion. Once expanded, the appropriate CAR is introduced into the cells by retroviral transduction. These effector CAR-T cells are then infused back into the patient where they can exert their cytotoxic effects on tumor cells.

To provide target cells for immuno-oncology researchers adopting BLI assays, we generated CAR-T Target Luciferase Reporter Cells that can be used to examine the function of CAR-T cells. These reporter cells naturally express high levels of clinically relevant CAR-T target antigens on the cell surface. ATCC’s CAR-T Target Luciferase Reporter Cells were derived from a variety of highly malignant liquid and solid cancer types, namely B cell lymphoma, Burkitt’s lymphoma, Non-Hodgkin’s B cell lymphoma, and ductal breast carcinoma. These novel target cells were generated from parental tumor cells that have high endogenous expression of target antigens such as CD19, CD20, and HER2. Stable luciferase-expressing clones were engineered to display high signal-to-noise ratios, aiding in data interpretation.

Download app note here